Are big pharmaceutical stocks in the midst of a turnaround?. “A turnaround could be at hand,” "Mad Money" host Jim Cramer said. “After years where...

Taking a Framework Approach to Securing Electronic Health Records (EHRs)Prepare Now for a Rational and Sustainable Pathway to New Healthcare...

EARNINGS MISS: Bristol-Myers Squibb Co. posts fourth-quarter adjusted earnings of $906 million, or 53 cents a share, on sales of $5.45 billion ...

Bristol-Myers Squibb Co failed to beat analysts' fourth-quarter profit estimates as the company invested in new products and sales fell for Plavix...

Not even a full month into the new year, it's already apparent that 2012 is going to be a busy one for mergers and acquisitions among drug and...

Drugmaker Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, due to higher sales of eight drugs, lower ...

Jan. 19 (Bloomberg) -- Bristol-Myers Squibb Co. and AstraZeneca Plc failed to win U.S. clearance to sell the first in a new class of experimental...

To no one's surprise, the FDA has rejected dapagliflozin, an SGLT2 inhibitor for diabetes. The advisory panel voted it down back during the summer...

18,353,397 shares of Bristol Myers Squibb Co. (BMY) traded hands on Thursday, a 72.86% increase in volume compared to its 20-day average. The stock...

Bristol Myers Squibb (NYSE: BMY) was downgraded by investment analysts at Morgan Stanley (NYSE: MS) to an "equalweight" rating in a note issued to...